Gigaxonin is required for intermediate filament transport.
giant axonal neuropathy
gigaxonin
intermediate filaments
kinesin-1
microtubules
neurofilaments
vimentin
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
23
02
2023
received:
20
12
2022
accepted:
08
03
2023
medline:
14
4
2023
entrez:
12
4
2023
pubmed:
13
4
2023
Statut:
ppublish
Résumé
Gigaxonin is an adaptor protein for E3 ubiquitin ligase substrates. It is necessary for ubiquitination and degradation of intermediate filament (IF) proteins. Giant axonal neuropathy is a pathological condition caused by mutations in the GAN gene that encodes gigaxonin. This condition is characterized by abnormal accumulation of IFs in both neuronal and non-neuronal cells; however, it is unclear what causes IF aggregation. In this work, we studied the dynamics of IFs using their subunits tagged with a photoconvertible protein mEOS 3.2. We have demonstrated that the loss of gigaxonin dramatically inhibited transport of IFs along microtubules by the microtubule motor kinesin-1. This inhibition was specific for IFs, as other kinesin-1 cargoes, with the exception of mitochondria, were transported normally. Abnormal distribution of IFs in the cytoplasm can be rescued by direct binding of kinesin-1 to IFs, demonstrating that transport inhibition is the primary cause for the abnormal IF distribution. Another effect of gigaxonin loss was a more than 20-fold increase in the amount of soluble vimentin oligomers in the cytosol of gigaxonin knock-out cells. We speculate that these oligomers saturate a yet unidentified adapter that is required for kinesin-1 binding to IFs, which might inhibit IF transport along microtubules causing their abnormal accumulation.
Identifiants
pubmed: 37043392
doi: 10.1096/fj.202202119R
pmc: PMC10237250
doi:
Substances chimiques
Cytoskeletal Proteins
0
Kinesins
EC 3.6.4.4
Intermediate Filament Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22886Subventions
Organisme : NIGMS NIH HHS
ID : P01 GM096971
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS127204
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS082351
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA060553
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM131752
Pays : United States
Informations de copyright
© 2023 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Eur J Hum Genet. 2000 Jul;8(7):527-34
pubmed: 10909853
J Cell Biol. 1983 Jun;96(6):1803-8
pubmed: 6682861
Rare Dis. 2013 Jun 17;1:e25378
pubmed: 25003002
Mol Biol Cell. 2011 Jul 1;22(13):2282-9
pubmed: 21562225
J Cell Sci. 2012 Jul 15;125(Pt 14):3257-63
pubmed: 22956720
Mol Neurodegener. 2011 Apr 12;6:25
pubmed: 21486449
FASEB J. 2023 May;37(5):e22886
pubmed: 37043392
Methods Mol Biol. 2009;586:187-206
pubmed: 19768431
Hum Genomics. 2013 May 15;7:13
pubmed: 23676014
Elife. 2021 Jul 27;10:
pubmed: 34313224
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):
pubmed: 29196434
J Neurochem. 2005 May;93(4):861-74
pubmed: 15857389
PLoS One. 2015 Oct 13;10(10):e0140157
pubmed: 26460568
J Cell Biol. 1998 Oct 5;143(1):147-57
pubmed: 9763427
J Clin Invest. 2013 May;123(5):1964-75
pubmed: 23585478
J Biol Chem. 2000 Jan 28;275(4):2795-803
pubmed: 10644744
Neurogenetics. 1997 Sep;1(2):129-33
pubmed: 10732815
World J Pediatr. 2018 Jun;14(3):298-304
pubmed: 29876741
J Cell Biol. 2010 Sep 6;190(5):719-29
pubmed: 20819932
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Biol Chem. 2015 Jul 10;290(28):17145-53
pubmed: 25957409
BMC Bioinformatics. 2021 Sep 10;22(1):433
pubmed: 34507520
J Cell Biol. 1992 Jun;117(6):1263-75
pubmed: 1607388
Mol Biol Cell. 2016 Feb 15;27(4):608-16
pubmed: 26700320
J Cell Biol. 1998 Oct 5;143(1):159-70
pubmed: 9763428
Acta Neuropathol Commun. 2014 Apr 24;2:47
pubmed: 24758703
Nature. 1991 Oct 3;353(6343):445-8
pubmed: 1832745
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3505-14
pubmed: 26109569
Acta Neuropathol. 1977 Aug 31;39(3):261-9
pubmed: 199032
Hum Mutat. 2003 Apr;21(4):446
pubmed: 12655563
Nat Rev Mol Cell Biol. 2007 Jul;8(7):562-73
pubmed: 17551517
Cell. 1998 Jun 26;93(7):1147-58
pubmed: 9657148
Mol Biol Cell. 2006 Apr;17(4):2057-68
pubmed: 16467387
Proc Natl Acad Sci U S A. 1985 Dec;82(23):7929-33
pubmed: 3865206
Neuromuscul Disord. 2007 Aug;17(8):624-30
pubmed: 17587580
Science. 1998 Jan 23;279(5350):514-9
pubmed: 9438837
Mol Biol Cell. 2016 Dec 15;27(25):3980-3990
pubmed: 27798231
Nat Rev Neurosci. 2012 Jan 05;13(2):77-93
pubmed: 22218207
Nat Neurosci. 2018 Oct;21(10):1332-1340
pubmed: 30250260
J Neuropathol Exp Neurol. 1976 Jul;35(4):458-70
pubmed: 180266
J Neurochem. 2008 Oct;107(1):253-64
pubmed: 18680552
FASEB J. 2019 Jan;33(1):388-399
pubmed: 29944446
Curr Opin Cell Biol. 2021 Feb;68:181-191
pubmed: 33454158
Nat Genet. 2000 Nov;26(3):370-4
pubmed: 11062483
Mol Biol Cell. 2008 Apr;19(4):1561-74
pubmed: 18256280
Hum Mol Genet. 2016 Jun 1;25(11):2143-2157
pubmed: 27000625
Mol Biol Cell. 2015 May 1;26(9):1675-86
pubmed: 25717187
J Cell Biol. 2003 Apr 14;161(1):55-66
pubmed: 12682084
Cell Syst. 2016 Sep 28;3(3):252-263.e8
pubmed: 27667364